このアイテムのアクセス数: 80

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
s41467-024-46605-0.pdf3.57 MBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.authorChen, Si Jingen
dc.contributor.authorHashimoto, Kazuyaen
dc.contributor.authorFujio, Kosukeen
dc.contributor.authorHayashi, Karinen
dc.contributor.authorPaul, Sudip Kumaren
dc.contributor.authorYuzuriha, Akinorien
dc.contributor.authorQiu, Wei-Yinen
dc.contributor.authorNakamura, Emirien
dc.contributor.authorKanashiro, Maria Alejandraen
dc.contributor.authorKabata, Mioen
dc.contributor.authorNakamura, Souen
dc.contributor.authorSugimoto, Naoshien
dc.contributor.authorKaneda, Atsushien
dc.contributor.authorYamamoto, Takuyaen
dc.contributor.authorSaito, Hirohideen
dc.contributor.authorTakayama, Naoyaen
dc.contributor.authorEto, Kojien
dc.contributor.alternative陳, 思婧ja
dc.contributor.alternative林, 香倫ja
dc.contributor.alternative杠 明憲ja
dc.contributor.alternative中村, 壮ja
dc.contributor.alternative杉本, 直志ja
dc.contributor.alternative山本, 拓也ja
dc.contributor.alternative齊藤, 博英ja
dc.contributor.alternative高山, 直也ja
dc.contributor.alternative江藤, 浩之ja
dc.date.accessioned2024-05-08T07:32:54Z-
dc.date.available2024-05-08T07:32:54Z-
dc.date.issued2024-03-22-
dc.identifier.urihttp://hdl.handle.net/2433/287580-
dc.descriptioniPS細胞由来血小板造血における免疫巨核球の制御機構の発見 血小板の大量製造に向けた巨核球マスターセルの品質管理に応用可能. 京都大学プレスリリース. 2024-03-26.ja
dc.descriptionDiscovering a new microRNA-regulated pathway to boost iPS cell-derived platelet production. 京都大学プレスリリース. 2024-03-26.en
dc.description.abstractWe recently achieved the first-in-human transfusion of induced pluripotent stem cell-derived platelets (iPSC-PLTs) as an alternative to standard transfusions, which are dependent on donors and therefore variable in supply. However, heterogeneity characterized by thrombopoiesis-biased or immune-biased megakaryocytes (MKs) continues to pose a bottleneck against the standardization of iPSC-PLT manufacturing. To address this problem, here we employ microRNA (miRNA) switch biotechnology to distinguish subpopulations of imMKCLs, the MK cell lines producing iPSC-PLTs. Upon miRNA switch-based screening, we find imMKCLs with lower let-7 activity exhibit an immune-skewed transcriptional signature. Notably, the low activity of let-7a-5p results in the upregulation of RAS like proto-oncogene B (RALB) expression, which is crucial for the lineage determination of immune-biased imMKCL subpopulations and leads to the activation of interferon-dependent signaling. The dysregulation of immune properties/subpopulations, along with the secretion of inflammatory cytokines, contributes to a decline in the quality of the whole imMKCL population.en
dc.language.isoeng-
dc.publisherSpringer Natureen
dc.rights© The Author(s) 2024en
dc.rightsThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/-
dc.subjectBiotechnologyen
dc.subjectPlateletsen
dc.subjectPluripotent stem cellsen
dc.titleA let-7 microRNA-RALB axis links the immune properties of iPSC-derived megakaryocytes with platelet producibilityen
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleNature Communicationsen
dc.identifier.volume15-
dc.relation.doi10.1038/s41467-024-46605-0-
dc.textversionpublisher-
dc.identifier.artnum2588-
dc.addressDepartment of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University; Department of Regenerative Medicine, Graduate School of Medicine, Chiba Universityen
dc.addressDepartment of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto Universityen
dc.addressDepartment of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto Universityen
dc.addressDepartment of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto Universityen
dc.addressDepartment of Regenerative Medicine, Graduate School of Medicine, Chiba Universityen
dc.addressDepartment of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto Universityen
dc.addressDepartment of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto Universityen
dc.addressDepartment of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto Universityen
dc.addressDepartment of Regenerative Medicine, Graduate School of Medicine, Chiba Universityen
dc.addressDepartment of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto Universityen
dc.addressDepartment of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto Universityen
dc.addressDepartment of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto Universityen
dc.addressDepartment of Molecular Oncology, Graduate School of Medicine, Chiba Universityen
dc.addressDepartment of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University; Medical-risk Avoidance Based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP)en
dc.addressDepartment of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto Universityen
dc.addressDepartment of Regenerative Medicine, Graduate School of Medicine, Chiba Universityen
dc.addressDepartment of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University; Department of Regenerative Medicine, Graduate School of Medicine, Chiba Universityen
dc.identifier.pmid38519457-
dc.relation.urlhttps://www.cira.kyoto-u.ac.jp/j/pressrelease/news/240326-110000.html-
dcterms.accessRightsopen access-
datacite.awardNumber21H05047-
datacite.awardNumber23K18299-
datacite.awardNumber.urihttps://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21H05047/-
datacite.awardNumber.urihttps://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23K18299/-
dc.identifier.eissn2041-1723-
jpcoar.funderName日本学術振興会ja
jpcoar.funderName日本学術振興会ja
jpcoar.awardTitle血小板産生メカニズムの基本原理解明と医療応用技術の展開ja
jpcoar.awardTitle免疫制御巨核球・血小板造血システムの理解に基づく老化制御法の開発ja
出現コレクション:学術雑誌掲載論文等

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons